In what now feels like a distant time, when business travelers were jet-setting around the world to attend meetings and events, some would tack on a couple of extra days to explore and enjoy the destination - a phenomenon that (for better or worse) has been dubbed "bleisure travel.
31 Dec 2020 marks the end of the Brexit transition period. As we get closer to this date - the theme tune to the game show 'Deal or No Deal' is in the back of our minds - it's natural to be concerned by the dizzying news emerging from negotiations in Brussels.
The pandemic has shaken our industry to the core, but this allows us to re-envision what we want business travel to look like in the future. As we emerge from this crisis, we have a unique opportunity to build a better future, taking a more balanced approach to travel management that embraces climate impact and wellbeing measures.
In September 2019, the CWT Meetings & Events (CWT M&E) team in Singapore held its inaugural MarketME event, providing a platform for buyers and suppliers in the industry to come together, exchange ideas and learn about the latest products, services, and trends in the market.
The COVID-19 pandemic has forced all organizations to take a closer look at their travel risk policies. Protecting the health and safety of travelers highlights the increasing importance of having a Duty of Care plan.
COVID-19 has changed nearly every organization; it's certainly changed the business travel world. Despite benefitting from video conferencing services (e.g. Zoom, WebEx, and Skype) we have realized that what matters most is the human touch.
Recent vaccine news - though being a cause for great optimism- may be making some people complacent, some scientific advisors have stated. Where there's complacency for some, there's anxiety for others.
In many countries globally, we are seeing second waves and there may be more to follow. We are beginning to see light at the end of the tunnel with the highly-promising emergence of vaccines with but there may be insufficient supply, at least initially, of a single vaccine.